AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01359020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, dipyrone, acetaminophen
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
Study NCT02671500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Study NCT01359020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen, dipyrone, acetaminophen
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
Study NCT03958006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: Tumor resection with cochlear implant
Study NCT04382846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide
Study NCT01390155 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
Study NCT01390155 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
Study NCT01390155 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
Study NCT01390155 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
Study NCT03725111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: venous compression
Description: venous compression
Study NCT04385758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-REM Program
Description: A comprehensive community paramedicine management program designed to support adults with uncontrolled diabetes and a recent emergency department visit or hospitalization
Study NCT00297804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Express Paclitaxel-Eluting Coronary Stent System
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT00297804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control stent
Description: control stent
Study NCT00873262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin test panel and desensitization kit
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
Study NCT00873262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Skin test panel and solvent
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
Study NCT00269906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Study NCT00269906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01895790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic Duct Stent Placement
Study NCT02222298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video assisted ablation of pilonidal sinus
Description: A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
Study NCT02222298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bascom Cleft lift procedure
Study NCT03591133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TS-143
Study NCT03591133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT04678531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Swabs containing tea tree oil and chamomile oil
Description: Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study NCT04678531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baby shampoo
Description: Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study NCT02149238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavanol
Study NCT02149238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: methylxanthine
Study NCT02149238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavanol + methylxanthine
Study NCT04200469 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Flow Ratio (QFR) measurement
Description: Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
Study NCT04946578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 6 weeks of prebiotic supplementation twice a day
Study NCT04946578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks of maltodextrin supplementation twice a day
Study NCT02388347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
Study NCT02388347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 1
Description: Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
Study NCT02388347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 2
Description: Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
Study NCT02388347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 3
Description: Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
Study NCT02388347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 4
Description: Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
Study NCT00554996 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: E. coli 83972 coated urinary catheter
Description: E. coli 83972 coated urinary catheter
Study NCT00609856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: tablet, 30 mg, once daily, 26 weeks
Study NCT00609856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
Study NCT02796768 — intervention group
Intervention type: OTHER
Intervention: 3D US Scanning
Description: 3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
Study NCT02796768 — intervention group
Intervention type: OTHER
Intervention: 2D US Scanning
Description: 2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
Study NCT01641653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2cc. one dose prior to OR
Study NCT01641653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2.5 mg
Study NCT04281251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde appendicitis therapy
Description: Colonoscopy would be introduced until visualization of the appendiceal orifice. Catheter would be placed in the appendix and decompression performed. After removal of appendicolith, plastic stent would be placed for drainage of appendix.~For patients successfully treated with initial endoscopic drainage, they would be re-admitted at 1 weeks after index procedure for repeat colonoscopy. After reaching the appendiceal orifice, the previous plastic stent would be removed. A contrast appendicogram would be repeated by introducing a wire-guided catheter in the appendix, and any residual fecalith would be removed. Finally, a repeat contrast appendicogram would be performed to confirm complete clearance of fecalith.
Study NCT03890198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-C182A cells
Description: Patients receive fludarabine (3×300 mg/ m\^2) and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
Study NCT01893489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 68Gallium-MSA
Description: 68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
Study NCT01893489 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 68Gallium-MSA
Description: 68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
Study NCT02270671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: Attention Bias Modification Training
Study NCT02270671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Training
Study NCT02881372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral food desensitization
Description: The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
Study NCT03348410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing with insurance officer
Study NCT04266015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition formula
Description: Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
Study NCT02081014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: stable, pre-mixed, liquid glucagon for subcutaneous injection
Study NCT03313492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UV4.me2
Description: UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~1. A mobile version of the site~2. Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~3. Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback
Study NCT03313492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UV4.me
Description: Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
Study NCT03313492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Pamphlet
Description: A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention.
Study NCT01490892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D HI and SHI of UCA
Description: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
Study NCT02980276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
Study NCT02980276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
Study NCT03430622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus
Description: LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.
Study NCT03430622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: This group will be on their routine care and will not be given any intervention
Study NCT02061878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
Study NCT02061878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
Study NCT00667459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE® LP Cervical Disc
Description: The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
Study NCT00667459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATLANTIS Anterior Cervical Plate
Description: Anterior cervical discectomy and fusion with ATLANTIS plate for control group
Study NCT01122875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFGR1877S
Description: Intravenous repeating dose
Study NCT00078377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 250 mg once daily in the morning
Study NCT00078377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg once daily in the morning
Study NCT00078377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily
Study NCT02354651 — intervention group
Intervention type: OTHER
Intervention: Diaphragm conditioning via phrenic nerve stimulation
Description: Diaphragm pacing will be prescribed by the patient's clinical team.
Study NCT00883974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitivity Training
Description: The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping.
Study NCT01381575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine 580299
Description: Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
Study NCT01381575 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' HPV vaccine 580299
Description: Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
Study NCT03112915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block
Description: QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
Study NCT03112915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plan block
Description: TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
Study NCT04697134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious Discipline-Based Environmental Enrichment Intervention
Description: Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
Study NCT01443403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets administered orally once a day.
Study NCT01443403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine tablets administered orally once a day.
Study NCT02344875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)
Study NCT01529489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted/Aerobic physical training
Description: COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
Study NCT01529489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval physical training in elliptical equipament
Description: Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
Study NCT01529489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval physical training in elliptical equipament
Description: COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
Study NCT01529489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resisted/Aerobic physical training
Description: Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
Study NCT04834713 — intervention group
Intervention type: OTHER
Intervention: clinical classification of HFRS
Description: Based upon clinical classification of HFRS , the patients were classified into four types
Study NCT00803192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine Tablets, 40 mg
Study NCT03680339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section
Description: CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers